Platelet News and Research

RSS

Platelet activation linked to osteoporosis

Elderly, postmenopausal women with osteoporosis have elevated platelet volumes, report researchers.

2 Jul 2012

Registry proves invaluable for fibromuscular dysplasia patients

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.

27 Jun 2012

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

27 Jun 2012

New melatonin analogues more efficient in inhibiting NOS activity in Parkinson's disease

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

22 Jun 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

14 Jun 2012

FDA clears Immunetics’ BacTx rapid test for bacterial contamination in platelet units

Immunetics, Inc., has received U.S. Food and Drug Administration (FDA) clearance for its BacTx rapid test for bacterial contamination in platelet units, Andrew E. Levin, Ph.D., Immunetics Chief Executive Officer and Scientific Director, announced today.

13 Jun 2012

Uncertainty over efficacy of clopidogrel in hemolytic uremic syndrome

Clinical outcomes for children hospitalized with diarrhea-associated hemolytic uremic syndrome are comparable between those treated with clopidogrel and those who are not, show study findings.

12 Jun 2012

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris.

11 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

FDA approves Arteriocyte’s ACD-A for use with Magellan system

Arteriocyte Medical Systems, Inc. announced today approval by the U.S. Food and Drug Administration (FDA) to manufacture and distribute the Arteriocyte Medical Systems brand of Anticoagulant Citrate Dextrose Solution, USP (ACD-A) for use with its Magellan Platelet Separation System.

5 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

UCSB creates synthetic platelets for various biomedical applications

Synthetic platelets have been developed by UC Santa Barbara researchers, in collaboration with researchers at Scripps Research Institute and Sanford-Burnham Institute in La Jolla, Calif. Their findings are published in the journal Advanced Materials in a paper titled "Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood."

31 May 2012

USPTO issues patent to Corgenix’s AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology.

30 May 2012

Fluxion Biosciences announces launch of Discovery Services business

Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it is launching a Discovery Services business to support growing demand for assay support on Fluxion's unique cell analysis platforms.

From Fluxion Biosciences 29 May 2012

UC Davis mathematicians help biologists to understand platelet formation

UC Davis mathematicians have helped biologists figure out why platelets, the cells that form blood clots, are the size and shape that they are. Because platelets are important both for healing wounds and in strokes and other conditions, a better understanding of how they form and behave could have wide implications.

28 May 2012

Blood platelet concentrates improve healing after dental implant procedures

Restoring the front teeth after a traumatic injury poses a particular challenge—biologically, functionally, and aesthetically. Even when all the procedures of a successful implant are followed, healing of tissues can still be an unpredictable element. One approach to improving the outcome of this type of implant is the use of blood platelet concentrates.

17 May 2012

Quasi-experimental data supports argument that air pollution may be a global risk factor for CVD

During the 2008 Beijing Olympics, changes in air pollution were associated with changes in biomarkers of systemic inflammation and thrombosis (formation of blood clot) as well as measures of cardiovascular physiology in healthy young persons, according to a study in the May 16 issue of JAMA, a theme issue on Global Health.

16 May 2012